WallStSmart

InMed Pharmaceuticals Inc (INM)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1330536% more annual revenue ($65.77B vs $4.94M). MRK leads profitability with a 13.6% profit margin vs -172.2%. MRK earns a higher WallStSmart Score of 50/100 (D+).

INM

Avoid

33

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -6.91

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for INM.

MRKSignificantly Overvalued (-52.6%)

Margin of Safety

-52.6%

Fair Value

$80.96

Current Price

$123.54

$42.58 premium

UndervaluedFair: $80.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INM2 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$308.90B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

INM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.14M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-143.8%2/10

ROE of -143.8% — below average capital efficiency

Revenue GrowthGrowth
-26.2%2/10

Revenue declined 26.2%

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : INM

The strongest argument for INM centers on Price/Book, Debt/Equity.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : INM

The primary concerns for INM are EPS Growth, Market Cap, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

INM profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

INM carries more volatility with a beta of 0.97 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

InMed Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

InMed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company is headquartered in Vancouver, Canada.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?